HLA-B*27 – unit dose Product Insert Page 1 of 12 101.531-48 – including *Taq* polymerase General "Instructions for Use"

IFU-01 Rev. No. 02 can be downloaded from

Lot No.: 84K Lot-specific information www.olerup-ssp.com

Olerup SSP® HLA-B*27 - unit dose

Product number: 101.531-48 – including *Taq* polymerase

Lot number: 84K

Expiry date: 2013-May-01

Number of tests: 48 Number of wells per test: 2

Storage - pre-aliquoted primers: dark at -20°C

- PCR Master Mix: -20°C
- Control DNAs: -20°C
- Adhesive PCR seals RT
- Product Insert RT

This Product Description is only valid for Lot No. 84K.

CHANGES COMPARED TO THE PREVIOUS OLERUP SSP® HLA-B*27 LOT

The HLA-B*27 specificity and interpretation tables has been updated for the HLA-B alleles described since the previous *Olerup* SSP[®] HLA-B*27 lot **(Lot No. 77G)** was made.

The HLA-B*27 unit dose primer set is unchanged compared to the previous lot.



HLA-B*27 – unit dose Product Insert Page 2 of 12 101.531-48 – including *Taq* polymerase General "Instructions for Use"

IFU-01 Rev. No. 02 can be downloaded from

Lot No.: 84K Lot-specific information www.olerup-ssp.com

PRODUCT DESCRIPTION

HLA-B*27 SSP typing

CONTENT

The primer set contains 5'- and 3'-primers for identifying the HLA-B27 specificity, B*27:01 to B*27:73.

Positive and negative control DNAs are included in the kit.

DNA 1; a B*27-positive DNA as a positive control, IHW 9315, CML, B*08:01,27:05:02.

DNA 2; a B*73-positive DNA as a negative control, **IHW 9280, LK707, B*52:01:01,73:01.** (A B*73:01-positive DNA was chosen as negative control, as this is most similar to the B*27 group of alleles in the primer matching regions.)

PLATE LAYOUT

Each test consists of 2 PCR reactions. 4 tests are aliquoted in each cut 8 well PCR plate.

1 2 1 2 1 2 1 2

The 8 well cut PCR plate is marked with 'B27' in silver/gray ink.

Well No. 1 is marked with the Lot No. '84K'.

A faint row of numbers is seen between wells 1 and 2 or wells 7 and 8 of the PCR trays. These stem from the manufacture of the trays, and should be disregarded.

The PCR plates are covered with a PCR-compatible foil.

Please note: When removing each 8 well PCR plate, make sure that the remaining plates stay covered. Use a scalpel or a similar instrument to carefully cut the foil between the plates.

INTERPRETATION

In addition to the HLA-B*27 alleles, the B*44:97 allele is amplified by primer mix 1 and the B*37:02, B*47:04 and B*47:05 alleles are amplified by primer mix 2 of the HLA-B*27 kit.

UNIQUELY IDENTIFIED ALLELES

All the HLA-B*27 alleles, i.e. **B*27:01 to B*27:73**, recognized by the HLA Nomenclature Committee in October 2010¹ are identified by the primers in the HLA-B*27 SSP kit.

In addition, the B*44:97 is amplified by primer mix 1 and the B*37:02, B*47:04 and B*47:05 alleles are amplified by primer mix 2 of the HLA-B*27 kit.

¹HLA-B alleles listed on the IMGT/HLA web page 2010-October-15, release 3.2.0, www.ebi.ac.uk/imgt/hla.

HLA-B*27 – unit dose **Product Insert** Page 3 of 12 101.531-48 – including *Taq* polymerase General "Instructions for Use"

IFU-01 Rev. No. 02 can be downloaded from

Lot No.: **84K** Lot-specific information www.olerup-ssp.com

PROTOCOL

DNA EXTRACTION

Extracted, highly pure DNA is needed for SSP typings. DNA samples to be used for PCR-SSP HLA typing should be re-suspended in dH2O. The A260/A280 ratio should be 1.6 - 2.0 by UV spectrophotometry for optimal band visualization during electrophoresis.

We recommend automated DNA extraction with the QIAGEN EZ1 DSP DNA Blood System. ACD blood should be used as starting material.

Alternatively, the DNA can be extracted by any preferred method yielding pure DNA. When using alternative methods, the DNA concentration should be adjusted to 30 ng/µl. Do not use heparinised blood with these methods.

Recommended DNA concentration using:

EZ1-extracted DNA, 15 ng/µl.

DNA extracted by other methods, 30 ng/µl.

Concentrations exceeding 50 ng/µl will increase the risk for nonspecific amplifications and weak extra bands, especially for HLA Class I high resolution SSP typings. If necessary, dilute the extracted DNA in dH₂O.

PCR AMPLIFICATION

101.531-48 - including Tag polymerase

For one HLA-B*27 typing add at room temperature in a 0.5 ml tube:

 $4 \times 2 \mu I = 8 \mu I DNA (30 ng/\mu I)$

 $4 \times 3 \text{ ul} = 12 \text{ ul}$ PCR Master Mix complete with Tag - mix well before taking your aliquot

 $4 \times 5 \mu l = 20 \mu l dH_2O$

Mix well, dispense 10 μl of the DNA-PCR Master Mix-H₂O mixture into each of the 2 wells of an HLA-B*27 typing. The 8 well PCR plate is marked with the lot number. Cover the primer tray(s) with the provided adhesive PCR seals. Check that all reaction wells are completely covered to prevent evaporative loss during PCR amplification. The Olerup SSP® Compression Pad (Product No. 103.505-06) can be applied on top of the adhesive PCR seals to prevent evaporation during thermal cycling.

HLA-B*27 – unit dose Product Insert Page 4 of 12
101.531-48 – including *Taq* polymerase General "Instructions for Use"

IFU-01 Rev. No. 02 can be downloaded from

Lot No.: 84K Lot-specific information www.olerup-ssp.com

PCR cycling parameters:

1.	1 cycle	94°C	2 min	denaturation
2.	10 cycles	94°C	10 sec.	denaturation
	-	65°C	60 sec.	annealing and extension
3.	20 cycles	94°C	10 sec.	denaturation
	-	61°C	50 sec.	annealing
		72°C	30 sec.	extension
4.	End - hold	RT		if less than 8 hours
		4°C		if longer than 8 hours

Total reaction volume in each well, 10 μl.

The same PCR cycling parameters are used for all the Olerup SSP kits.

AGAROSE GEL ELECTROPHORESIS

Prepare a 2% (w/v) agarose gel in 0.5 x TBE buffer. Dissolve the agarose by boiling in a microwave oven. Let the gel solution cool to 60° C. Stain the gel prior to casting with ethidium bromide (10 mg/ml), 5 μ l per 100 ml gel solution. For maximal ease of handling use our ethidium bromide dropper bottles (Product No. 103.301-10). Note: Ethidium bromide is a carcinogen. Handle with appropriate personal protective equipment.

Load the PCR products, preferably using an 8-channel pipette. Load a DNA size marker (100 base pair ladder, DNA Size Marker Product No. 103.202-100 or DNA Size Marker for short gel runs 103.203-100) in one well per row.

Run the gel in 0.5 x TBE buffer, without re-circulation of the buffer, for 15-20 minutes at 8-10 V/cm.

DOCUMENTATION AND INTERPRETATION

Put the gel on a UV transilluminator and document by photography.

Record the presence and absence of specific PCR products. The length of the specific PCR product is helpful in the interpretation of the results.

Record the presence of the internal positive control bands.

Lanes without either control band or specific PCR products should be repeated.

Interpret the typings with the *lot-specific Interpretation and Specificity Tables*.



HLA-B*27 – unit dose Product Insert Page 5 of 12
101.531-48 – including *Taq* polymerase General "Instructions for Use"

IFU-01 Rev. No. 02 can be downloaded from

Lot No.: 84K Lot-specific information www.olerup-ssp.com

PCR MASTER MIX

The PCR Master Mix including with *Taq* polymerase contains:

Taq polymerase 0.4 unit per 10 μl SSP reaction

nucleotides final concentration of each dNTP is 200 μ M PCR buffer final concentrations: 50 mM KCl, 1.5 mM MgCl₂,

10 mM Tris-HCl pH 8.3, 0.001% w/v gelatin

glycerol final concentration of glycerol is 5%

cresol red final concentration of cresol red is 100 µg/ml

The same PCR Master Mix is used for all Olerup SSP kits including Taq polymerase.

When stored at -20° C, the PCR Master Mix including Taq polymerase is stable for 27 months from the date of manufacture.

Page 6 of 12 General "Instructions for Use"

IFU-01 Rev. No. 02 can be downloaded from

Lot No.: 84K Lot-specific information www.

www.olerup-ssp.com

SPECIFICITY TABLE

HLA-B*27 SSP typing

Specificity and size of the PCR product of the two primer mixes used for HLA-B*27 SSP typing.

Primer Mix	Size of spec. PCR product ¹	Size of control band ²	Amplified HLA-B*27 alleles	Other amplified HLA-B alleles ³
1	145 bp	430 bp	*27:01-27:05:08, 27:05:10- 27:11, 27:13-27:15, 27:17, 27:19-27:21, 27:24-27:25, 27:27-27:28, 27:30, 27:32- 27:73	*44:97
2 ⁴	95 bp	515 bp	*27:01-27:05:15, 27:08, 27:10, 27:12-27:13, 27:15- 27:18, 27:23, 27:25-27:26, 27:28-27:29, 27:31, 27:36- 27:40, 27:42, 27:44-27:45, 27:47-27:69, 27:71-27:73	*37:02, 47:04- 47:05

¹Alleles are assigned by the presence of specific PCR product(s). However, the sizes of the specific PCR products may be helpful in the interpretation of HLA-B*27 SSP typings.

When the primers in a primer mix can give rise to specific PCR products of more than one length this is indicated if the size difference is 20 base pairs or more. Size differences shorter than 20 base pairs are not given. For high resolution SSP kits the respective lengths of the specific PCR product(s) of the alleles amplified by these primer mixes are given.

Nonspecific amplifications, i.e. a ladder or a smear of bands, may sometimes be seen. GC-rich primers have a higher tendency of giving rise to nonspecific amplifications than other primers.

PCR fragments longer than the control bands may sometimes be observed. Such bands should be disregarded and do not influence the interpretation of the SSP typings.

PCR fragments migrating faster than the control bands, but slower than a 400 bp fragment may be seen in some gel read-outs. Such bands can be disregarded and do not influence the interpretation of the SSP typings.

Some primers may give rise to primer oligomer artifacts. Sometimes this phenomenon is an inherit feature of the primer pair(s) of a primer mix. More often it is due to other factors such as too low amount of DNA in the PCR reactions, taking too long time in setting up the PCR reactions, working at elevated room temperature or using thermal cyclers that are not pre-heated

²The internal positive control primer pairs amplify segments of the human growth hormone gene. The two different control primer pairs give rise to either an internal positive control band of 430 base pairs or a band of 515 base pairs.

Well number 1 contains the primer pair giving rise to the shorter, 430 bp, internal positive control band in order to help in the correct orientation of the HLA-B*27 typing.

In the presence of a specific amplification the intensity of the control band often decreases.

³Due to the sharing of sequence motifs between HLA-B alleles the B*44:97 is amplified by primer mix 1 and the B*37:02, B*47:04 and B*47:05 alleles are amplified by primer mix 2.

⁴Short specific PCR fragments are less intense and not as sharp as longer specific bands.

IFU-01 Rev. No. 02 can be downloaded from

Lot No.: 84K Lot-specific information wv

www.olerup-ssp.com

INTERPRETATION TABLE **HLA-B*27 SSP typing** Amplification pattern of the B*27:01 to 27: 73 alleles¹ Well 1 2 145 Length of spec. 95 Length of spec. **PCR** product **PCR** product Length of int. 430 515 Length of int. pos. control pos. control² 5'-primer³ 167 363 5'-primer³ 5' -gCT 3' ^{5'} -AAT ^{3'} 272 418 3'-primer⁴ 3'-primer4 5' -TgC 3' 5' -gTC 3' Well No. 2 Well No. HLA-B allele⁵ HLA-B allele5 *27:01-27:05:08, 27:05:10-27:05:15, *27:01-27:05:08, 27:05:10-27:05:15, 27:08, 27:10, 27:13, 27:15, 27:17, 27:08, 27:10, 27:13, 27:15, 27:17, 27:25, 27:28, 27:36-27:40, 27:42, 2 27:25, 27:28, 27:36-27:40, 27:42, 1 27:44-27:45, 27:47-27:69, 27:71-27:44-27:45, 27:47-27:69, 27:71-27:73 *27:05:09, 27:12, 27:16, 27:18, 27:23, *27:05:09, 27:12, 27:16, 27:18, 27:23, 2 27:26, 27:29, 27:31, *37:02, 47:04-*27:26, 27:29, 27:31, *37:02, 47:04*-47:05 47:05 *27:06-27:07, 27:09, 27:11, 27:14, *27:06-27:07, 27:09, 27:11, 27:14, 27:19-27:21, 27:24, 27:27, 27:30, 27:19-27:21, 27:24, 27:27, 27:30, 1 27:32-27:35, 27:41, 27:43, 27:46, 27:32-27:35, 27:41, 27:43, 27:46, **27:70**, *44:*97 **27:70**, *44:*97 HLA-B allele⁵ HLA-B allele⁵ Well No. Well No.

¹Due to the sharing of sequence motifs between HLA-B alleles the B*44:97 is amplified by primer mix 1 and the B*37:02, B*47:04 and B*47:05 alleles are amplified by primer mix 2.

Well number 1 contains the primer pair giving rise to the shorter, 430 bp, internal positive control band in order to help in the correct orientation of the HLA-B*27 typing.

In the presence of a specific amplification the intensity of the control band often decreases.

December 2010

Rev. No.: 00

The B*2722 sequence has been shown to be identical to the corrected B*27:06 sequence.



²The internal positive control primer pairs amplify segments of the human growth hormone gene. The two different control primer pairs give rise to either an internal positive control band of 430 base pairs or a band of 515 base pairs.

³The nucleotide position, in the 2nd and 3rd exons, matching the specificity-determining 3'-end of the primer is given. Nucleotide numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

⁴The nucleotide position, in the 2nd and 3rd exons, matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

⁵The sequence of the B*270501 allele has been shown to be identical to B*27:05:02.

IFU-01 Rev. No. 02 can be downloaded from

Lot-specific information Lot No.: **84K**

www.olerup-ssp.com

	OCILIA INC. VALIDATION CHEET						
C	CELL LINE VALIDATION SHEET HLA-B*27 unit dose SSP kit						
	П	LA-D'Z/ Unit (10se 33				
				We	_	_	
					1	2	
				Production No.	201080601	201080602	
	IH	WC cell line	HL	A-B			
1	9001		*07:02		-	-	
2	9280	LK707	*52:01	*73:01	-	-	
3	9011	E4181324	*52:01		-	-	
4	9275	GU373	*15:10	*53:01	-	-	
5	9009	KAS011	*37:01		-	-	
6	9353		*39:01	*51:01	-	-	
7	9020		*18:01		-	-	
8	9025		*35:01		-	-	
9	9026		*38:01		-	-	
10		LKT3	*54:01		-	-	
11		PITOUT	*44:03		-	-	
12	9052		*57:01		-	-	
13		JESTHOM	*27:05		+	+	
14		OLGA	*15:01	*15:20	-	-	
15	9075		*40:01		-	-	
16		SWEIG007	*40:02		-	-	
17		CTM3953540	*08:01	*55:01	-	-	
18		32367	*14:01	*56:01	-	-	
19		BM16	*18:01		-	-	
20		SLE005	*40:01		<u> </u>	-	
21		AMALA	*15:01		-	-	
22		KOSE	*35:03	*50.00	-	-	
23	9124		*40:02	*56:02	-	-	
24		JBUSH	*38:01		-	-	
25		IBW9	*14:02		-	-	
26		WT49	*58:01	*54.04	-	-	
27		CH1007	*07:05	*51:01	-	-	
28		BEL5GB MOU	*44:02 *44:03	*44:03	-	H	
29 30	9050		*42:01		<u> </u>		
		DUCAF	-		Ė	븬	
31 32		HAG	*18:01 *41:02		Ë	-	
33		MT14B	*40:01		Ē		
34	9104		*38:01		Ē		
35		SSTO	*44:02		Ē		
36		KT17	*15:01	*35:01	-		
37		HHKB	*07:02	55.01	-		
38	9099		*15:01		l	-	
39	9315		*08:01	*27:05	+	+	
40		WHONP199	*13:02	*46:01	Ė	-	
41		H0301	*14:02	. 5.5 1	Ι-	-	
42		TAB089	*46:01		۱-	-	
43		T7526	*46:01		-	-	
44	9057		*38:01		-	-	
45		SHJO	*42:01	*50:01	-	-	
46		SCHU	*07:02	33.01	۱-	-	
47		TUBO	*51:01		۱-	-	
48		TER-ND	*35:01	*44:03	-	-	
+0	3303	ILIV-IND	33.01	44.03	ـــَـــا	لت	

December 2010

Rev. No.: 00

HLA-B*27 – unit dose Product Insert Page 9 of 12

101.531-48 – including *Taq* **polymerase**General "Instructions for Use"

IFU-01 Rev. No. 02 can be downloaded from

Lot No.: 84K Lot-specific information www.olerup-ssp.com

CERTIFICATE OF ANALYSIS

Olerup SSP® HLA-B*27 SSP - unit dose

Product number: 101.531-48 – including *Taq* polymerase

Lot number: 84K

Expiry date: 2013-May-01

Number of tests: 48 Number of wells per test: 2

Well specifications:

Well No.	Production No.	
1	2010-806-01	
2	2010-806-02	

The specificity of the primer solutions of the kit has been tested against 48 well characterized IHWC cell line DNAs.

Results: No false positive or false negative amplifications were obtained.

Date of approval: 2010-December-09

Approved by:

Quality Control, Supervisor

HLA-B*27 – unit dose Product Insert Page 10 of 12 101.531-48 – including *Taq* polymerase General "Instructions for Use"

IFU-01 Rev. No. 02 can be downloaded from

Lot No.: 84K Lot-specific information www.olerup-ssp.com

Declaration of Conformity

Product name: Olerup SSP® HLA-B*27 - unit dose

Product number: 101.531-48

Lot number: 84K

Intended use: HLA-B*27 low resolution histocompatibility testing

Manufacturer: Olerup SSP AB

Hasselstigen 1

SE-133 33 Saltsjöbaden, Sweden

Phone: +46-8-717 88 27 **Fax:** +46-8-717 88 18

We, *Olerup* SSP AB, hereby declare that this product, to which this Declaration of Conformity relates is in conformity with the following Standard(s) and other normative document(s) ISO 9001:2008 and ISO 13485:2003, following the provisions of the 98/79/EC Directive on *in vitro* diagnostic medical devices, Annex II List B, conformity assessed using Annex IV, as transposed into the national laws of the Member States of the European Union.

The Technical Documentation File is maintained at *Olerup* SSP AB, Hasselstigen 1, SE-133 33 Saltsjöbaden, Sweden.

The Authorized Representative located within the Community is: Olerup SSP AB.

Notified Body: Lloyd's Register Quality Assurance Limited, Hiramford, Middlemarch Office Village, Siskin Drive, Coventry CV3 4FJ, United Kingdom. (Notified Body number: 0088.)

Saltsjöbaden, Sweden 2010-December-09

Olle Olerup Managing Director HLA-B*27 – unit dose Product Insert Page 11 of 12
101.531-48 – including Taq polymerase General "Instructions for Use"

IFU-01 Rev. No. 02 can be downloaded from

Lot No.: 84K Lot-specific information www.olerup-ssp.com



HLA-B*27 – unit dose Product Insert Page 12 of 12 101.531-48 – including *Taq* polymerase General "Instructions for Use"

IFU-01 Rev. No. 02 can be downloaded from

Lot No.: 84K Lot-specific information www.olerup-ssp.com

Addresses:

Manufacturer:

Olerup SSP AB, Hasselstigen 1, SE-133 33 Saltsjöbaden, Sweden.

Tel: +46-8-717 88 27 **Fax:** +46-8-717 88 18

E-mail: info-ssp@olerup.com

Web page: http://www.olerup-ssp.com

Distributed by:

Olerup GmbH, Löwengasse 47 / 6, AT-1030 Vienna, Austria.

Tel: +43-1-710 15 00 **Fax:** +43-1-710 15 00 10

E-mail: support-at@olerup.com **Web page:** http://www.olerup.com

Olerup Inc., 901 S. Bolmar St., Suite R, West Chester, PA 19382

Tel: 1-877-OLERUP1 **Fax:** 610-344-7989

E-mail: info.us@olerup.com

Web page: http://www.olerup.com

For information on Olerup SSP distributors worldwide, contact Olerup GmbH.

